Kusano M, Nakanishi M, Matsushima T, Sakamoto S, Sekiya C, Une Y, Suga M, Kawamura A, Koito K, Uekita Y
Department of Surgery, Asahikawa Medical College, Hokkaido, Japan.
Cancer Chemother Pharmacol. 1992;31 Suppl:S146-9. doi: 10.1007/BF00687125.
The Hokkaido Liver Cancer Study Group focused on the changes in PIVKA-II levels observed in 61 HCC patients after several regimens of treatment in comparison with the AFP levels and the pathophysiological characteristics of HCC. The overall positivity rate for PIVKA-II was 47%, and there was no correlation between the PIVKA-II values and the AFP levels. Accordingly, the HCC detection rate was increased by about 20% by the measurement of both markers. In all, 13 patients underwent hepatic resection, and nonsurgical therapy was carried out in the other 48 subjects. Of the 6 surgically treated patients, 5 (83%) showed a fall in PIVKA-II levels to the normal range immediately after surgery, whereas 14/29 (48%) subjects receiving nonsurgical treatment showed a decrease in PIVKA-II values. Although inconsistency between these tumor markers was detected in four treated cases, we concluded that assay for both of these two parameters may expand their clinical utility for the diagnosis of HCC and monitoring of patients after treatment.
北海道肝癌研究小组关注61例肝癌患者在接受几种治疗方案后观察到的异常凝血酶原-II（PIVKA-II）水平变化，并与甲胎蛋白（AFP）水平及肝癌的病理生理特征进行比较。PIVKA-II的总体阳性率为47%，且PIVKA-II值与AFP水平之间无相关性。因此，通过检测这两种标志物，肝癌的检出率提高了约20%。共有13例患者接受了肝切除术，其他48例患者接受了非手术治疗。在6例接受手术治疗的患者中，5例（83%）术后异常凝血酶原-II水平立即降至正常范围，而在接受非手术治疗的29例患者中有14例（48%）异常凝血酶原-II值下降。尽管在4例接受治疗的病例中检测到这两种肿瘤标志物之间存在不一致，但我们得出结论，检测这两个参数可能会扩大它们在肝癌诊断和治疗后患者监测中的临床应用价值。
